Document is current
Any future updates will be listed below
-
Authors
Hörber, Sebastian http://orcid.org/0000-0002-5718-1530
Prystupa, Katsiaryna
Jacoby, Johann
Fritsche, Andreas
Kleber, Marcus E.
Moissl, Angela P.
Hellstern, Peter
Peter, Andreas
März, Winfried
Wagner, Robert
Heni, Martin
-
Funding
Funding for this research was provided by:
Universitätsklinikum Tübingen
- License Information
-
More Information
Article History
Received: 18 June 2024
Accepted: 10 August 2024
First Online: 22 August 2024
Declarations
:
: The study protocol had been approved by the local institutional review board (Ethics committee of the Landesärztekammer Rheinland-Pfalz, No. 1997–203). The study was performed in adherence with the principles of the Declaration of Helsinki and its later amendments. All volunteers provided written informed consent to participate in the study.
: Not applicable.
: RW reports lecture fees from Novo Nordisk, Sanofi-Aventis, Boehringer-Ingelheim and Eli Lilly. He served on the advisory board for Akcea Therapeutics, Daiichi Sankyo, Sanofi-Aventis, Eli Lilly and NovoNordisk. Outside of the current work, MH reports research grants from Boehringer Ingelheim and Sanofi (both to the University Hospital of Tübingen) and lecture fees from Amryt, Astra Zeneca, Bayer, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk, and Sanofi. He also served on advisory boards for Amryt, Boehringer Ingelheim, and Sanofi. All other authors had nothing to disclose.
